Össur hf. - Financial Statement Release

Ossur hf. - Second Quarter Report 2009

Second Quarter 2009 Financial Highlights

  * Sales USD 81.3 million, down by 3% measured in LCY, or 12% in USD
  * EBITDA USD 17.0 million, down by 11%
  * EBITDA margin 21%, same as in Q2 2008
  * Net profit USD 3.5 million, compared to USD 3.9 million in Q2
    2008
  * EPS diluted 0.83 US cents, compared to 0.93 US cents in Q2 2008
  * Cash EPS diluted 3.2 US cents, compared to 2.4 in Q2 2008

First Half 2009 Financial Highlights

  * Sales USD 158.5 million, down by  3% measured in LCY, or 12% in
    USD
  * EBITDA USD 29.8 million, down by 29%
  * EBITDA margin 19%, compared to 23% in H1 2008
  * Net profit USD 11.1 million, compared to USD 10.6 million in H1
    2008
  * EPS diluted 6.84 US cents, up by 45%
  * Cash EPS diluted 11.92 US cents, up by 21%


Jon Sigurdsson, President & CEO, comments:"Slowdown of the economy in the Company's major markets has affected
sales, as customers are cautious due to the uncertainty.
Discontinuation of third party agreements in EMEA has a temporary
negative effect on sales but not on profitability. Strong leadership
and clear strategy in sales and marketing in the US give comfort
towards positive developments. A new version of the bionic knee Rheo
as well as the acceptance of the Proprio foot into the US
reimbursement channel are important milestones for the future of the
bionic platform.


The press release including tables, the Investor Presentation Q2 2009
and the Financial Statement Q2 2009 can be downloaded from the
following links:

Attachments:

Q2 2009 Market Presentation.pdf

Ossur hf Financial Statements June 09.pdf

Ossur Q2 Press Release.pdf